A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma

A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03739320

Enrollment

Registered

2018-11-13

Start date

2017-12-11

Completion date

2019-12-31

Last updated

2018-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Eosinophilic Asthma

Keywords

severe asthma, biologic therapy, physical activity monitoring

Brief summary

Daily physical activity in adult patients with asthma remains overlooked. Limited evidence demonstrates reduced levels of daily physical activity in asthma populations but studies examining the potential effect of available therapies are missing. This study aims to investigate the overall levels of daily physical activity in patients with severe eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of existing, maximal, and optimised asthma treatment, may improve patient's daily physical activity.

Detailed description

A multi-centre, prospective, observational study of continuous patients who fulfil the definition of severe asthma and the criteria for mepolizumab (nucala; GSK) therapy. Patients have their daily physical activity recorded using triaxial accelerometry (DynaPort MoveMonitor; McRoberts) prior to treatment, and at 6 and 12 months of mepolizumab therapy (100 mg subcutaneously once every 4 weeks).

Interventions

DRUGMepolizumab 100 MG Injection [Nucala]

100 milligrams subcutaneously once every 4 weeks

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Severe asthma 2. Criteria for mepolizumab therapy: blood eosinophils ≥150 cells/μL at screening or ≥300 cells/μL in the past 12 months.

Exclusion criteria

Comorbidities limiting physical activity

Design outcomes

Primary

Measure	Time frame	Description
Change in daily moving time	7 days	Moving time in minutes
Change in daily movement intensity	7 days	Movement intensity in m/s\^2
Change in daily time in moderate-to-vigorous-intensity activity	7 days	Time in moderate-to-vigorous-intensity activity in minutes
Change in daily steps	7 days	Step count

Countries

Greece

Contacts

Primary ContactMarios Panagiotou, MD

mpanagiotou@med.uoa.gr+306974238267

Backup ContactNikoletta Rovina, MD

nikrovina@med.uoa.gr+306945830212‬

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026